Xspray Pharma: Investment Case Materializing - Redeye

Redeye envisions an exciting period on the horizon for Xspray Pharma following the resolution of the Dasynoc patent litigation with BMS. We consider the settlement a validation of Xspray's technology and perceive a risk reduction associated with the investment case. As a result, we rework our forecasts and DCF, adjusting our fair value range accordingly.

Länk till analysen i sin helhet: https://www.redeye.se/research/943337/xspray-pharma-investment-case-materializing?utm_source=finwire&utm_medium=RSS